The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published standardized guidance on the selection and management of patients receiving lutetium-177-labeled PSMA-617 radionuclide therapy for metastatic castration-resistant prostate cancer. The guidance, published in The Journal of Nuclear Medicine, provides recommendations for patient selection criteria and appropriate use scenarios for LuPSMA therapy. It states that PSMA positron-emission tomography (PET) should be performed within 3 months of treatment or since progression on the last therapy to ensure accurate representation of the disease state. PSMA PET imaging can use either fluorine F-18-DCFPyL or gallium Ga-68-PSMA-11, and F-18-fluorodeoxyglucose PET is not required. The guidelines also address baseline requirements, appropriate treatment scenarios, and clinical struggles physicians may face during treatment. The authors of the consensus statement expressed anticipation for the potential use of PSMA radionuclide therapy in prechemotherapy metastatic castration-resistant prostate cancer.
Thu, 07 Sep 2023 18:26:47 GMT | The ASCO Post